Healthcare
cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products
cbdMD, Inc. (NYSE American: YCBD), one of the nation's most recognized and trusted hemp-derived wellness companies, today welcomed the Administration's call urging Congress to ensure the fair treatment of hemp-derived products under federal law and requesting immediate action to revise federal hemp regulation to ensure fair treatment of hemp products under federal law.
About this update from Cbdmd, Inc.
As federal reclassification efforts advance and major U.S. exchanges open to compliant operators, cbdMD points to its position as an established, NYSE American–listed company in a maturing cannabinoid category CHARLOTTE, N.C., June 25, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's most recognized and trusted hemp-derived wellness companies, today welcomed the Administration's call urging Congress to ensure the fair treatment of hemp-derived products under federal law and requesting immediate action to revise federal hemp regulation to ensure fair treatment of hemp products under federal law. In a letter to congressional leadership this week, the White House Office of Management and Budget identified hemp reform as a priority the Administration strongly supports. The request calls on Congress to ensure fair treatment of hemp-derived products by preserving access to appropriate full-spectrum CBD products, while preserving Congress's intent to restrict products that pose health risks. The Administration also urged Congress to adopt a responsible federal framework or, at minimum, extend the current implementation timeline so that lawmakers have time to get the policy right. The request builds on the President's earlier public statements urging lawmakers to protect access to the full-spectrum CBD products that millions of Americans rely on. "We are encouraged to see the Administration advocating so clearly for responsible, science-backed hemp products that consumers depend on every day," said Ronan Kennedy, Chief Executive Officer of cbdMD. "cbdMD has always believed the future of this category is built on quality, transparency, and clear rules that distinguish responsible operators from bad actors. A federal framework that protects consumer access, promotes safety, and provides certainty for compliant companies is exactly what this industry and the people it serves deserve. We commend the policymakers who are working toward that outcome." Separately, broader federal cannabis policy developments continue to draw investment, research, and institutional attention to the cannabinoid category. Notably, major U.S. exchanges have begun permitting the listing of the plan-touching operators that comply with federal, state and local medical cannabis framework. Although cannabis reclassification is distinct from the federal treatment of hemp-derived products, recent exchange-listing developments for compliant cannabis operators reflect a market that is moving toward greater legitimacy, transparency, and regulatory maturity. As an established hemp-derived wellness company with recognized brands, national distribution, and a listing on a national securities exchange, cbdMD believes it is well-positioned as the cannabinoid category moves toward greater maturity, transparency, and regulatory clarity.